Other

OCI available-for-sale securities adjustment

Vertex Pharmaceuticals OCI available-for-sale securities adjustment decreased by 52.7% to $3.50M in Q3 2025 compared to the prior quarter. Year-over-year, this metric declined by 94.8%, from $66.70M to $3.50M. This decline may warrant attention — for this metric, higher values are generally preferred.

Analysis

StatementIncome Statement
SectionOther
CategoryOther
SignalHigher is better
VolatilityVolatile
First reportedQ1 2015
Last reportedQ3 2025

How to read this metric

An increase indicates rising market values for the company's debt portfolio, while a decrease suggests market-driven depreciation of these assets.

Detailed definition

This metric represents the net change in the fair value of debt securities classified as available-for-sale, recognized...

Peer comparison

Common in financial institutions and large-cap firms with significant treasury investment portfolios.

Metric ID: is_jpm_oci_available_for_sale_securities

Historical Data

8 periods
 Q1 '23Q2 '23Q3 '23Q4 '23Q2 '24Q3 '24Q2 '25Q3 '25
Value$2.43M$2.43M$2.43M$2.43M-$5.40M$66.70M$7.40M$3.50M
QoQ Change+0.0%+0.0%+0.0%-322.7%>999%-88.9%-52.7%
YoY Change-322.7%>999%+237.0%-94.8%
Range-$5.40M$66.70M
CAGR+23.3%
Avg YoY Growth+617.5%
Median YoY Growth+71.1%
Current Streak2 quarters decline

Frequently Asked Questions

What is Vertex Pharmaceuticals's oci available-for-sale securities adjustment?
Vertex Pharmaceuticals (VRTX) reported oci available-for-sale securities adjustment of $3.50M in Q3 2025.
How has Vertex Pharmaceuticals's oci available-for-sale securities adjustment changed year-over-year?
Vertex Pharmaceuticals's oci available-for-sale securities adjustment decreased by 94.8% year-over-year, from $66.70M to $3.50M.
What does oci available-for-sale securities adjustment mean?
The net unrealized gain or loss on debt investments held for sale, recorded outside of net income.

Cookie Preferences

We use cookies for analytics. See our Privacy and Cookie Policy.